MDH2 and non-small cell lung carcinoma: Moreover, recent studies have demonstrated that modulating the malate–aspartate shuttle pathway through the inhibition of glutamate-oxaloacetate transaminase 2 or MDH2 can trigger cell death and diminish adenosine triphosphate levels in non-small cell lung cancer, akin to the impact of glutaminase 1 inhibition [56].